Following Noselab´s successful presentations at CTAD 2023 and the BioCapital Europe Investor Conference, we are all set to showcase our innovative diagnostic platform at the highly anticipated 2024 AD/PD Conference in Lisbon, Portugal.
Learn more about Noselab’s pioneering work at AD/PD 2024, where we unveil our groundbreaking diagnostic platform!
Our Latest News
In our second publication, we present further details of our novel, safe and non-invasive diagnostic platform. Learn more about the scientific principle, platform benefits and applications of our revolutionary diagnostic approach.
Read our prime publication and learn more about Noselab’s revolutionary diagnostic approach.
Be part of our journey as we join the esteemed AD/PD™ 2024 International Conference on Alzheimer's and Parkinson's Diseases! Visit us in Lisbon from March 5th to 9th, 2024. At our booth (#19) we will present our revolutionary diagnostic platform approach based on nasal-derived CSF (nCSF) and related research milestones.
At the esteemed 2024 BioCapital Europe Investor Conference, Noselab GmbH made waves with its revolutionary diagnostic breakthrough. CEO Thomas Heydler revealed their groundbreaking proprietary diagnostic platform, aiming to transform the lives of patients with neurodegenerative diseases (ND), with an initial focus on Alzheimer’s Disease.